Therefore, to overcome imatinib resistance, novel analogues of Imatinib such as ponatinib, nilotinib, dasatinib, bosutinib, etc., have been developed as TKIs and tested in patients with BCR-ABL positive CML. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.